Botulax, Dermalax.

Jul. 2009

Oct. 2009

Dec. 2009

Jan. 2010

Feb. 2010

Mar. 2010

Jun. 2010

July. 2010

Jun. 2011

Aug. 2011

Oct. 2011

Establishes the Hugelpharma Co., Ltd. Obtains a license for Medicine and medical supplies wholesaler Obtains a license for tissue bank Starts Rib Cartilage distribution of Life link Tissue Starts Rib Cartilage distribution of CG Bio Establishes key opinion leader consultative group of Hugelpharma Co., Ltd. Holds Botulax Launching Ceremony Starts Botulax distribution in domestic market Begins Hugelpharma Academy Starts developing multi needle therapy system device (Trade name : Automeso) 1st anniversary of Botulax: 3003 clinics, 16.1billion KRW of sales Starts meso injector device distribution in domestic market Launch of self-developed Automeso (Start domestic sales and exportation)

Hugel to develop aesthetic market with

advanced products.

Hugel is no.1 be company in Korea for

Aesthetic market.

STAGE I

Build sales network

~2011 2012~2013 2014 2015~

STAGE II

Build-up advanced R&D and Product pipe line

STAGE III

Leading domestic Aesthetic Market

STAGE IV

International growth company

Strengthen the base

Growing business in various Aesthetic fields

The best products in each Aesthetic field

1st ranked pharmaceutical company in Aesthetic fields

* Raise management and operation abilities through ERP

* Reinforcement of Sales & Marketing Dept.

* Recruit world-class R&D specialists and scientific specialists

* Build up top quality R&D system in Korea

* Construction of world-class R&D base

• Build CRM system • New Factory in EUGMP Class

* Construction of marketing system structure

* Develop technology for combination therapies

* Hold many international patents

* Build up strategic management system

* Secure advanced ability for all value chains

* Create added value through the strategic management system

* Hold the high quality biological products in Korea

Domestic market expansion Secure driving force of growth

Active strategic alliance and acquisitions

Construct internal management system Strengthen capabilities Build up sound management and creative innovative work forces

Expand marketing activities in the overseas market If necessary, push into overseas market

Hugel to plan long term strategy for world

wide market.

Hugel to extend pipe line of

medicine and device for Aesthetic Market

Medicine

- Zentox (Botulax)

Botulinum Toxin Type A (CBFC:26)

- Dermal Filler : Dermalax

- PPC injection : Lipobean known as

Korea’s Britney spears injection

Medical Device

-Automeso (FNS)

Micro Needle Therapy System

- Meso Injector

- Meso Solutions

Aesthetic Implant

-Breast bag :

Looking for a partner

-Surgical Implant :

Looking for a partner

2015-10-19

Botulax to have 2nd brand of Botulax in

Southern Asia with same quality.

2015-10-19

Botulax to have 3 BESTs as same as

Bests Feature Benefit

Potency • Zentox’s potency is about 10% more

than Botox (Allergan).

• Strong efficacy, Quick on set time.

• Strict Quality Control

- confidence limit, safety and

98% manufacturing efficiency.

• Longer duration than Botox.

• Higher patient’s satisfaction.

• Consistent therapeutic

results.

Price /

Image

• Competitive Price vs. Botox

• Korean Wave to compete against

Botox in Asia.

• Improve the profit of clinics.

• Increase no. of new

patients.

Service • Best relationship with Korea KOLs.

• Various marketing program are

available.

• Positioning as hub clinic via

direct connection with Korea

KOLs.

2015-10-19

Hugel to have relationships with TOP10 and

about 3,000 clinics in aesthetics clinics.

Hospital Specialty Location Web page

BK Dongyang

PS Hospital

Ostectomy, Fat graft , Breast implant,

Liposuction, Rhinoplasty, Eyelid surgery

Seoul www.bkhospital.com

Wonjin PS clinic Ostectomy, Fat graft , Breast implant,

Liposuction, Rhinoplasty, Eyelid surgery

Seoul www.parkwonjin.co.kr

JK PS clinic Ostectomy, Fat graft , Breast implant,

Liposuction, Rhinoplasty, Eyelid surgery

Seoul www.jkplastic.com

Banobagi PS clinic Ostectomy, Fat graft , Breast implant,

Liposuction, Rhinoplasty, Eyelid surgery

Seoul www.banobagi.com

Gyarumhan PS clinic Ostectomy,, Fat graft , BTX-a/Filler

Liposuction, Rhinoplasty, Eyelid surgery

Seoul www.gyarum.com

Leaders Dermatology Clinic Dermatology Network Seoul www.beautyleader.co.kr

Oracle Dermatology Clinic Dermatology Network Seoul www.oracleclinic.com

Gowunsesang

Dermatology Clinic

Dermatology Network Seoul http://www.beautyforever.co.

kr

WINN clinic Laser, Liposuction, ETC Seoul www.wynnclinic.com

The All clinic Laser, Liposuction, ETC Seoul www.theallmc.com

2015-10-19

Botualx(Zentox) to prove superiority

to Botox(Allergan) in non-clinical data

2015-10-19

Botualx(Zentox) also proves efficacy

with clinical trial.

2015-10-19

A Split Face Single-blind Clinical Study Comparing Two Botulinum Toxin Type A Products

Lee, Soo-Keun, M.D., Ph.D. Mein Skin Clinic, Seoul, Korea - Consulting Doctor of Department of Dermatology, Seoul National University Hospital, Seoul, Korea Objective: To compare the efficacy and side effects profiles of Botulax® with a popularly used botulinum toxin type A product (hereinafter referred to as "BT”). Results: Average age of patients in the crow’s feet and squared face group were 50(32~63) and 27.5(21~32) years, respectively. The VAS in the crow’s feet group of before, 1 week and 4 months after the treatment were 8, 3, 6.5 in the Botulax® side and 7.3, 3.3, 6.5 in the BT side. The VAS in the squared face group of before, 1 month and 4 months after the treatment were 6.6, 3.3, 2.7 in the Botulax® side and 6.4, 3.6, 2.6 in the BT side. There were no significant differences of VAS changes and side effects profiles in both group.

Conclusion: Regarding the clinical effects and the side effects profiles on the crow’s feet and squared face (benign masseteric hypertrophy), the Korean made botulinum toxin type A or Botulax® seems to be nearly the same as the popularly used product. References : 1. Lee SK. The Clinical Results of a Korean made Botulinum Toxin Type A, Botulax®. Presented at the 13th Autumn Symposium of the Association of Korean Dermatologists, 2010 Nov. 14, Seoul, Korea. 2. Lee SK. Textbook of Botulinum Toxin and Filler. Seoul: Hanmi Medical Publishing Co., 2011.

Posted by 2012 AMWC

#1. Reference for Zentox(Botulax)

2015-10-19

#2. Reference for Zentox(Botulax)

Clinical comparisons of Botulax® & others on same patients

Koh, Ik Soo M.D., Ph.D. Plastic Surgeon, Petit Noble Aesthetic Clinic, KOREA

OBJECTIVE I had tested the Botox®, Myobloc® and Xeomin® to wrinkles and masseteric muscle hypertrophy by the same procedure to the patient in the same way in a year and half and I reported those results of the treatment. Botulax® is the new Botulinum toxin from south Korea which needs to prove the verification of its stability and effect unlike the global products. Therefore, I added comparison of Botulax® to studies of other toxins (Botox®, Myobloc® and Xeomin®) MATERIAL The author treated 3 patients to Myobloc®, Xeomin®, Botox®, Botulax® from Feb.2009 to Sep.2010. The injection sites were frown line, crow's feet, forehead wrinkles and masseteric muscle reduction. the strength of injections were lower clinically used concentrations for increasing sensitivity of the experiment.

CONCLUSION

In a comparative experiment, Botulax® has fast and strong strength onset than Botox® or Xeomin®. Botulax® will be able to establish itself as a new product with the long-term observation. Presented in 2nd International Congress of Minimal Invasive Plastic Surgery & Dermatology

10-12 SEPTEMBER 2010. COEX, SEOUL, KOREA

2015-10-19

The effect of Regenox on skin rejuvenation

Koichiro Kameyama Aoyama Dermatology Clinic

Methods : 100 units Regenox was diluted to 6ml by 0.9 % sodium chloride and injected to the patients. 500 units Dysports (also Botulinum toxin type A) was diluted to 10ml. The clinical effects of Regenox(Botulax) and Dysport were compared on some patients. Regenox(Botulax) or Dysports were chiefly injected just under epidermis, and sometimes I njected into the muscle. One shot is 0.025 ml, very low dose, to avoid the side effects.

Conclusion : Regenox(Botulax) improved the skin structure observed by skin scope. Regenox(Botulax) increased the number of keratinocytes and the amounts of collagen fiber on upper dermis. However, Regenox(Botulax) did not show direct effect on the cells or amounts of collagen in vitro.

Presented in THE ASOSSIATION OF KOREAN DERMATOLOGISTS, 2010. 4. 4

#3. Reference for Zentox(Botulax)

2015-10-19

Dermalax, new HA filler

2015-10-19

Dermalax to be new HA filler with made by

Hugel

Type DERMALAX plus

DERMALAX Deep plus

DERMALAX

IMPLANT plus

Composition 20mg/ml stabilized

hyaluronic acid

Lidocaine 0.3%

20mg/ml stabilized hyaluronic

acid

Lidocaine 0.3%

20mg/ml stabilized

hyaluronic acid

Lidocaine 0.3%

Recommended

indications

Thin superficial lines.

Such as worry lines,

Periobital lines, Perioral

lines,

Folds, such as nasolabial

folds. Shaping facial contours,

e.g. cheeks and chin lips,

fullness and pouting

Folds, such as

nasolabial folds.

Shaping facial

contours, e.g. cheeks

and chin lips, fullness

and pouting

Where to inject Upper part of dermis Deep layer of dermis and/of

Middle layer of sub cutis

Deep layer of subcutis

Volume of

syringe

1.0mL 1.0mL 1.0ml

Needle size 30G 27G 23G

Duration 6-12 months 6-12 months 6-12month

Storage 2~28oC 2~28oC 2~28oC 2015-10-19

Specification of Dermalax

Factor Specification Result

Appearance No Impurities, Colorless and transparent

gel Pass

Identification Reference spectrum should match Pass

PH 6.5 ~ 7.5 7.0

BDDE residues Less than 2.0ppm 0 PPm

Heavy metal Less than 10.0ppm 10PPm under

pressure 12 ~25N 18.7 ± 0.3N

omolalitys 200~ 400 mOsm/kg 311mOsm/kg

Volume More than 1.0mL 1.1mL

Asepsis aseptic aseptic

Endotoxins Less than 12.5EU/mL < 0.1EU/mL

Assay 18.0 ~ 22mg/mL 18.9 ± 0.3mg/mL

2015-10-19

THANK YOU.

2015-10-19